Low Testosterone: Characterization and Treatment
Low testosterone is definitively characterized by a total testosterone level below 300 ng/dL measured on two separate early morning blood draws, combined with specific symptoms such as reduced libido, erectile dysfunction, fatigue, or decreased muscle mass. 1
Diagnostic Criteria
Biochemical Threshold
- Total testosterone <300 ng/dL is the diagnostic cutoff 1
- Must be confirmed with two separate measurements, both obtained in early morning (7-11 AM) 1
- Use the same laboratory and methodology for consistency 1
Required Clinical Features
The diagnosis requires BOTH low testosterone AND symptoms/signs. Laboratory values alone are insufficient. 1
Key symptoms to assess:
- Sexual: reduced libido, erectile dysfunction, decreased ejaculate volume
- Physical: reduced energy/endurance, diminished work performance, fatigue, loss of body/facial hair
- Cognitive: poor concentration, impaired memory, depression, reduced motivation, irritability 1
Physical examination findings:
- Body habitus and virilization status (body hair patterns in androgen-dependent areas)
- BMI or waist circumference
- Gynecomastia
- Testicular size, consistency, masses
- Varicocele presence
- Prostate size and morphology 1
Adjunctive Testing Algorithm
After confirming low testosterone, measure LH and FSH to distinguish etiology: 1
If LH/FSH are elevated: Primary testicular failure (testicular problem)
If LH/FSH are low or inappropriately normal: Secondary hypogonadism (hypothalamic-pituitary problem)
- Measure serum prolactin 1
- If prolactin persistently elevated: evaluate for pituitary adenoma or other endocrine disorders 1
- Consider MRI of pituitary, iron studies (hemochromatosis), and other pituitary hormone assessment 2
High-Risk Populations Requiring Screening
Even without symptoms, measure testosterone in men with: 1
- Unexplained anemia
- Bone density loss
- Diabetes mellitus
- Chemotherapy or testicular radiation exposure
- HIV/AIDS
- Chronic narcotic use
- Male infertility
- Pituitary dysfunction
- Chronic corticosteroid use
Important caveat: Do NOT diagnose testosterone deficiency during acute or subacute illness, as testosterone levels are transiently suppressed 3. Wait until recovery.
Treatment Approach
Who Should Receive Testosterone Therapy
Treat men who meet ALL three criteria: 1
- Confirmed low testosterone (<300 ng/dL on two morning measurements)
- Presence of symptoms/signs attributable to testosterone deficiency
- No absolute contraindications
Do NOT treat: 4
- Men with low testosterone but no symptoms
- Men seeking treatment solely for energy, vitality, physical function, or cognition without sexual symptoms (evidence shows minimal benefit) 4
- All older men with age-related low testosterone as a blanket policy 2
Treatment Options
Multiple formulations are available; selection depends on patient preference, cost, and tolerability: 2
Intramuscular injections:
- Testosterone enanthate or cypionate: 75-100 mg weekly OR 150-200 mg every 2 weeks 2
- Target testosterone levels 400-700 ng/dL measured 1 week post-injection 2
Transdermal patches:
- 5 mg testosterone patches applied nightly to back, thigh, or upper arm (avoid pressure areas) 2
Topical gels:
- 5-10 g of 1% testosterone gel applied daily to non-genital skin
- Patients must wash hands after application 2
Buccal tablets:
- 30 mg bioadhesive tablet applied to buccal mucosa every 12 hours 2
Treatment goal: Achieve mid-normal testosterone range (450-600 ng/dL) 5
Absolute Contraindications
Do NOT initiate testosterone therapy in men with:
- Prostate or breast cancer
- Erythrocytosis or hyperviscosity
- Untreated obstructive sleep apnea
- Severe heart failure 6
Monitoring Protocol
Initial follow-up at 3-6 months: 2, 5
- Assess symptom response (particularly sexual function)
- Check testosterone levels (aim for mid-normal range)
- Measure hematocrit
- Check PSA (in men ≥40 years)
- Evaluate for adverse effects
Ongoing monitoring (every 6-12 months): 2, 5
- Testosterone levels
- Hematocrit
- PSA (men ≥40 years)
- Metabolic parameters
- Symptom assessment
- Compliance evaluation
Obtain urological consultation if: 2
- PSA increase >1.4 ng/mL within any 12-month period
- PSA velocity >0.4 ng/mL/year (using 6-month level as reference, requires >2 years data)
- Abnormal digital rectal examination
- AUA/IPSS score >19
Expected Benefits
Evidence supports testosterone therapy for: 5, 7
- Sexual function improvement (libido, erectile function) - small to moderate effect 8, 5
- Quality of life - small improvement 8
- Body composition (increased lean mass, decreased fat mass) 5
- Bone mineral density improvement 5, 7
- Metabolic profile improvement 5
Limited or no benefit for: 4
- Energy and vitality
- Physical function
- Cognitive function
- Depressive symptoms
Safety Considerations
Cardiovascular safety: Recent large randomized trials demonstrate testosterone therapy does NOT increase risk of myocardial infarction or stroke, even in high-risk patients 7. This contradicts earlier concerns and should reassure clinicians 1.
Prostate cancer: Current evidence fails to definitively support increased prostate cancer risk with testosterone therapy 1, though men with existing prostate cancer should not receive treatment.
Common pitfall: Approximately 25% of men receiving testosterone therapy do not meet diagnostic criteria 1. Ensure proper diagnosis before initiating treatment. Nearly half of treated men never have follow-up testosterone levels checked 1—this represents substandard care.